[1]
JommiC., CiprianiF., FanelliF., PedoneM. P., and CanonicaW., “The effects of disease cross-coverage by dupilumab on the costs sustained by the Italian National Health Service”, GRHTA, vol. 7, no. 1, pp. 33-39, Jul. 2020.